DEF 14A: Mirion Technologies Announces 2024 Annual Stockholders' Meeting and Highlights Strong 2023 Performance

Mirion Technologies invites stockholders to its virtual 2024 Annual Meeting on June 4, 2024, following a year marked by significant order growth and strong financial results.

Summary

• Mirion Technologies will hold its 2024 Annual Stockholders' Meeting virtually on June 4, 2024.
• 2023 was a strong year for Mirion, with order growth of 22% compared to 2022.
• The company closed the year with a record backlog of $857 million.
• Fiscal year 2023 financial results included revenue of $801 million, a net loss of $99 million, and Adjusted EBITDA of $181 million.
• Mirion acquired the ec2 business in 2023 to enhance its nuclear medicine workflow software platform.
• The company published its first Corporate Sustainability Report in 2023, highlighting its commitment to ESG principles.
• Stockholders are encouraged to vote on the election of directors, ratification of the independent auditor, and the advisory vote on executive compensation.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with strong order growth and backlog, but the net loss tempers the overall sentiment. The focus on ESG and future opportunities contributes to a moderately positive assessment.

Positives

• Strong order growth indicates increasing demand for Mirion's products and services.
• Record backlog provides revenue visibility for future periods.
• The acquisition of ec2 enhances Mirion's product portfolio and market position.
• The publication of the Corporate Sustainability Report demonstrates a commitment to ESG, which can attract socially responsible investors.

Negatives

• The company reported a net loss of $99 million for fiscal year 2023.

Risks

• The document does not explicitly detail risks, but the net loss suggests potential challenges in profitability.
• Macro trends in nuclear power and nuclear medicine are subject to regulatory and political changes.

Future Outlook

The company believes it is well-positioned for long-term success due to macro trends in nuclear power and nuclear medicine.

Management Comments

• 2023 was an excellent year for Mirion, supported by robust market conditions across our end markets.
• We are committed to living out our mission of harnessing our unrivaled knowledge of ionizing radiation for the greater good of humanity.
• We believe that we maintain a leadership position in 16 of our 19 major product categories and we are committed to innovating and digitizing our portfolio to deliver further value to our customers and improve safety conditions in the vital industries we serve.
• In nuclear power, we continue to see governments, political groups and regulatory agencies continue to declare nuclear power as a green energy source and key pillar in the global push for decarbonization.
• Within nuclear medicine, the growing theranostics movement gives us encouragement for the health and longevity of the end market going forward.

Industry Context

The document highlights Mirion's position within the nuclear power and nuclear medicine industries, noting the growing recognition of nuclear power as a green energy source and the expansion of theranostics in healthcare.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or competitors.
• The peer group used for compensation benchmarking includes companies like IDEXX Laboratories, Polaris Industries, and Rockwell Automation, suggesting a focus on diversified industrial and technology companies.

Management Changes

Corporate Governance

Related Party Transactions

• The document details related party transactions, including the IntermediateCo Charter, Director Nomination Agreements, Amended and Restated Registration Rights Agreement, Founder Shares, Profits Interests, and Private Placement Warrants.
• The Audit Committee has a formal Related Party Transaction Policy to review and approve or ratify such transactions.

Stakeholder Impact

• The company's performance and governance practices impact shareholders, employees, customers, and suppliers.
• The focus on ESG and sustainability is intended to benefit all stakeholders.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will continue to execute its strategy to capitalize on macro trends in nuclear power and nuclear medicine.
• Mirion will continue to advance its ESG journey and report on its progress.

Key Dates

Keywords

Mirion Technologies, Annual Meeting, Stockholders, Order Growth, Backlog, Revenue, Adjusted EBITDA, Nuclear Power, Nuclear Medicine, Sustainability, ESG, Proxy Statement